Abstract
Ubiquitination is a critical post-translational modification in cancer-related pathways. Human deubiquitinases (DUBs), which modulate this process, comprise a family of approximately 100 proteins that primarily function by cleaving ubiquitin chains from substrates. The Machado-Joseph domain-containing proteases (MJDs) represent a specific DUB sub-family consisting of four members: Ataxin-3, Ataxin-3L, JOSD1, and JOSD2. While historically linked to Machado-Joseph disease, recent studies have revealed their significant roles in cancer progression. This review summarizes the cellular functions, regulatory mechanisms, and genetic alterations of MJDs across various human cancers, highlighting their potential as therapeutic targets.
Introduction
Ubiquitination serves as a molecular "code" governing protein degradation, localization, and signaling. Deubiquitinases (DUBs) act as the editors of this code. The MJD family is the smallest of the seven DUB families. Historically, research focused on Ataxin-3 due to its role in Spinocerebellar Ataxia Type 3 (SCA3), a neurodegenerative disorder caused by toxic polyglutamine (polyQ) expansions. However, the broader physiological roles of MJDs, particularly in oncology, have remained fragmented. This paper provides a unified perspective on how these four enzymes function and how their dysregulation contributes to both neurodegeneration and malignancy.
Structural and Functional Diversity
The MJD family members share a conserved catalytic core known as the Josephin domain. Despite high sequence identity between members like Ataxin-3 and Ataxin-3L (85%), their activities differ significantly. Ataxin-3’s activity is naturally restrained by specific residues, suggesting that small molecules could potentially "unlock" or further inhibit its function.
Furthermore, cellular localization defines their unique roles. JOSD1 is membrane-associated, regulating endocytosis and cell motility, whereas JOSD2 is primarily cytosolic, involved in general protein maintenance.
Pan-Cancer Genomic Analysis
To identify the clinical relevance of MJDs in oncology, the authors performed a pan-cancer genomic analysis using the cBioPortal database (TCGA data). This analysis mapped mutations, amplifications, and deletions across dozens of cancer types to identify which MJDs are most relevant to specific malignancies.
Key Findings in Cancer
- Oncogenic Potential: JOSD1 and JOSD2 are primarily amplified in melanoma, ovarian, and uterine cancers. JOSD1 specifically stabilizes the anti-apoptotic protein MCL1 in gynecological cancers, promoting chemoresistance by preventing its degradation.
- Context-Dependent Roles: Ataxin-3 and Ataxin-3L show higher frequencies of mutation or deletion in bladder and lung cancers. Notably, Ataxin-3 acts as a transcriptional repressor of the tumor suppressor PTEN in lung and testicular cancers; high Ataxin-3 levels correlate with low PTEN and increased tumor growth.
Role in Machado-Joseph Disease (SCA3)
In its physiological state, Ataxin-3 interacts with E3 ligases (such as CHIP and parkin) to facilitate the clearance of misfolded proteins. In SCA3, polyQ expansion leads to Ataxin-3 aggregation. This results in a "double hit" of toxic gain-of-function from aggregates and a loss of normal protein quality control. Emerging evidence also suggests that epigenetic factors, such as DNA methylation at the Ataxin-3 promoter, may influence the stability of pathogenic CAG repeats.
Conclusion and Future Perspectives
MJDs are emerging as critical regulators in both neurodegeneration and cancer. While they represent promising therapeutic targets, several challenges remain. There is currently a lack of potent, selective small-molecule inhibitors for MJDs compared to other DUB families. Additionally, the biological role of Ataxin-3L remains poorly understood. Future research must correlate MJD expression with clinical outcomes in patient samples to validate these enzymes as viable biomarkers and drug targets.
Summary updated